Home · About Us · Mission & Vision · The Science · Pipeline · Team · Contact · Investors
Investment Opportunity
Biophage, Inc. is a Texas biotechnology company developing precision bacteriophage therapies to combat antimicrobial-resistant bacterial disease in horses, livestock, and farmed fish. We are raising capital to advance our lead program and expand our phage discovery pipeline across agriculture and aquaculture.
Why Biophage
A large, underserved market. Our lead program targets Streptococcus equi, the cause of strangles — the most prevalent and economically damaging infectious disease in horses worldwide. Our platform extends the same approach to livestock and to aquaculture, where bacterial disease (including Aeromonas and Streptococcus pathogens in farmed fish) is a major, fast-growing, and underserved animal-health market.
Rising antimicrobial resistance. Antibiotic resistance is accelerating across veterinary and agricultural medicine, and targeted phage therapies offer a differentiated, microbiome-sparing alternative.
A defined regulatory path. Programs map to EPA antimicrobial biopesticide routes and FDA veterinary drug pathways, with a milestone-driven development timeline.
Clinician-led leadership. Founded and led by Benjamin Rice Buchanan, DVM, DACVIM, DACVECC — board-certified in both Large Animal Internal Medicine and Emergency & Critical Care — with an existing clinical network and deep frontline experience managing these infections.
The Raise
What we’re raising: Biophage is raising a $1.5M pre-seed round (target — final amount to be confirmed) to fund lead-program phage discovery, in vitro efficacy validation, and EPA/FDA regulatory groundwork over the next 18–24 months.
• Instrument: SAFE (Simple Agreement for Future Equity), on standard Y Combinator terms.
• Use of funds: phage isolation and characterization against Streptococcus equi; benchtop and in vivo proof-of-concept; contract-lab program with Ecolyse; and pre-submission engagement with the EPA and FDA.
• Key milestones this round funds: validated lead phage cocktail for strangles, a defined regulatory pathway, and readiness for a first pilot study.
• Minimum check: to be confirmed — contact us to discuss allocation.
We are actively speaking with aligned investors and strategic partners. Detailed materials — including our pitch deck, financial model, and development plan — are available in our confidential data room to parties who have executed a non-disclosure agreement.
We are structuring this round using a SAFE (Simple Agreement for Future Equity) — a widely used, founder- and investor-friendly early-stage investment instrument. To learn how a SAFE works, see the independent explainer and standard documents published by Y Combinator, the accelerator that created the instrument: What is a SAFE? (Y Combinator).
Request Access / Contact
To discuss the opportunity or request access to confidential materials, please contact us at info@biophagecorp.com.
NDA & Data Room Access
Access to our confidential data room — including the pitch deck, financial model, development plan, and regulatory strategy — is available to investors and partners who have executed a non-disclosure agreement.
To request access: download the NDA below, sign it, and return the executed copy to info@biophagecorp.com. Once we receive it, we will provide the confidential data room link and password.
